Increased Preclinical Efficacy of Irinotecan and Floxuridine Coencapsulated Inside Liposomes Is Associated With Tumor Delivery of Synergistic Drug Ratios
Keywords: Colorectal cancer; Combination chemotherapy; Floxuridine; Irinotecan; Liposome delivery; Synergy
Document Type: Research Article
Affiliations: 1: Celator Pharmaceuticals Corp., Vancouver BC, V6P 6P2 Canada 2: Celator Pharmaceuticals Corp., Vancouver BC, V6P 6P2 Canada, Celator Pharmaceuticals Inc., Princeton, NJ 08540, USA
Publication date: 01 August 2006
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.
- Editorial Board
- Information for Authors
- Submit a Paper
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content